Patricia Walker

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton et autres

us, nl, cn, gb, au, br, gr, at, es, il, fr, it, nz, hu, cz, ar, kr, jp, dk (code pays fourni par la source)

441 Improving Life with CF: feasibility and adult outcomes from a multi-site US primary palliative care trial

A. Georgiopoulos, Stephanie DiFiglia, Elizabeth K. Seng, Russell K. Portenoy et autres

111 Effect of hormonal contraception on rates of pulmonary exacerbations in women with cystic fibrosis

N. West, Chao-Yu Hsu, Amalia Magaret, Farooq A. Khan et autres

SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Ruddy Dalfeor, Constantine S. Tam, Paolo Ghia, Mazyar Shadman et autres

br, au, it, us, gb (code pays fourni par la source)

POSTER: CLL-745 SEQUOIA 5-Year Follow-up in Arm C: Frontline Zanubrutinib in Patients With del(17p) and Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. TamMB, Paolo Ghia, Mazyar Shadman, Talha Munir et autres

CLL-745: SEQUOIA 5-Year Follow-up in Arm C: Frontline Zanubrutinib in Patients With del(17p) and Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. TamMBBS, Paolo Ghia, Mazyar Shadman, Talha Munir et autres

au, it, us, gb, py (code pays fourni par la source)

Liver function among women with cystic fibrosis who use hormonal contraception

Jennifer Chin, Monika Sarkar, Amalia Magaret, Patricia Walker et autres

us (code pays fourni par la source)

SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Constantine S. Tam, Paolo Ghia, Mazyar Shadman, Talha Munir et autres

au, it, us, gb (code pays fourni par la source)

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik et autres

us, hu, pl, gb, nz, br, il, ca, au, it, be, fr, jp (code pays fourni par la source)

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R. Brown et autres

us, gb, pl, it, cz, se, au, at, nz, fr, ru, es, cn (code pays fourni par la source)

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik et autres

us, hu, pl, gb, nz, br, il, ca, au, se, it, fr (code pays fourni par la source)

Supplementary Data from The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Alessandra Tedeschi, Kim Linton, Pam McKay et autres